• Explore /
  • Poster
  • / Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.

Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial.

Abstract Poster

Authors

null

Yuan Xia

Breast Tumor Center, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China

Yuan Xia , Wenqian Yang , Ya-Ping Yang , Yingying Zhu , Yinduo Zeng , Tao Qin , Shijie Jia , Jiayi Chen , Chang Gong

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Breast Cancer—Local/Regional/Adjuvant

Track

Breast Cancer

Sub Track

Neoadjuvant Therapy

Clinical Trial Registration Number

NCT05165225

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr TPS620)

DOI

10.1200/JCO.2022.40.16_suppl.TPS620

Abstract #

TPS620

Poster Bd #

384b

Abstract Disclosures

Similar Posters

First Author: Christian Eichler

First Author: Takashi Ishikawa

First Author: E. Alba

First Author: G. Somlo